{"Clinical Trial ID": "NCT00448591", "Intervention": ["INTERVENTION 1:", "Bevacizumab", "Participants received bevacizumab 15 mg/kg iv on day 1 of each 3-week cycle, or 10 mg/kg iv on day 1 of each 2-week cycle (equivalent weekly dose of 5 mg/kg/week) at the same time as prescribed taxane chemotherapy."], "Eligibility": ["Incorporation criteria:", "<=18 years;", "HER-2 negative adenocarcinoma of the breast, with locally recurrent or metastatic disease; (HER-2 positive patients only if previously treated with Herceptin in the adjuvant setting;", "- Chemotherapy candidates.", "- Exclusion criteria:", "Previous chemotherapy for metastatic or locally recidivating breast cancer;", "Concomitant hormonal treatment for metastatic or locally recurrent diseases;", "- Concomitant treatment with Herceptin for the treatment of positive HER-2 metastatic or local recidivant disease;", "Previous radiation therapy for the treatment of metastatic diseases;", "Evidence of CNS metastases."], "Results": ["Performance measures:", "Percentage of participants with adverse reactions (ADRs) and serious AEs related to bevacizumab, death and special interest AEs (SAEs)", "The adverse reactions (including laboratory abnormalities) were evaluated by the investigator according to the classification systems of the National Cancer Institute - Common Toxicity Criteria (NCI-CTC).", "Time: Day 1 of cycles 1, 2, 3, 4, 5 and 6 up to 6 months after the last infusion of bevacizumab", "Results 1:", "Title of the arm/group: Bevacizumab", "- Arm/group description: Participants received bevacizumab 15 mg/kg iv on day 1 of each 3-week cycle, or 10 mg/kg iv on day 1 of each 2-week cycle (equivalent weekly dose of 5 mg/kg/week) at the same time as prescribed taxane chemotherapy", "Total number of participants analysed: 2264", "Type of measurement: Number", "Unit of measure: % of participants All EA: 95,4", "CTC grade 3, 4 or 5 AE: 57.6", "AE related to bevacizumab: 64.2", "All serious EA: 29,7", "\u2022 serious bevacizumab-related SAE: 7.6", "All deaths: 53.1", "AESI: 71.8"], "Adverse Events": ["Undesirable Events 1:", "Total: 672/2264 (29.68%)", "* 117/2264 (5.17 per cent)", "Neutropenia * 98/2264 (4.33%)", "* 14/2264 (0.62%)", "Anemia * 8/2264 (0.35%)", "Leucopenia * 8/2264 (0.35%)", "Thrombocytopenia * 6/2264 (0.27%)", "Disseminate intravascular coagulation * 3/2264 (0.13%)", "Agranulocytosis * 1/2264 (0.04%)", "* 1/2264 (0.04%)"]}